Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions

Trial Profile

Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2015

At a glance

  • Drugs BI 2536 (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2012 Planned number of patients changed from 185 to 220 as reported by European Clinical Trials Database record.
    • 08 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
    • 04 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top